Phase 3 Readout~month
Phase 3 Topline: A Randomized, Double-masked, Controlled, Safety and Tolerability Study of VRDN-003 in Participants W
- Drug
- vrdn-003
- Indication
- Thyroid Eye Disease (TED)
Other upcoming events for VRDN
Track this catalyst and more
Get real-time alerts, AI-powered analysis, and full catalyst coverage.